Accuray FRAME-PROSTATE study finds TomoTherapy delivers strong long-term survival in prostate cancer patients

Accuray FRAME-PROSTATE study finds TomoTherapy delivers strong long-term survival in prostate cancer patients
Accuray 10-year trial results

Accuray has released 10-year results from the FRAME-PROSTATE trial, demonstrating that TomoTherapy image-guided, moderate hypofractionation radiotherapy after prostatectomy yields excellent overall survival rates and very low late gastrointestinal toxicity.

These findings could influence future post-surgical treatment options for prostate cancer patients, supporting wider consideration of TomoTherapy in clinical protocols. Further details from the trial may guide both clinicians and patients navigating post-prostatectomy care.

Accuray previously reported that helical TomoTherapy was associated with significantly reduced xerostomia compared to VMAT in advanced nasopharyngeal carcinoma patients, citing improved protection of parotid glands in clinical data from a separate study. In another development, the company unveiled the Radixact and Helix systems to expand options for flexible helical radiotherapy at ESTRO26. These technologies highlight Accuray’s ongoing efforts to advance precision cancer treatment.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.